RT Journal Article
SR Electronic
T1 A polygenic score-based approach to identify gene-drug interactions stratifying breast cancer risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.03.21256511
DO 10.1101/2021.05.03.21256511
A1 Marderstein, Andrew R.
A1 Kulm, Scott
A1 Peng, Cheng
A1 Tamimi, Rulla
A1 Clark, Andrew G.
A1 Elemento, Olivier
YR 2021
UL http://medrxiv.org/content/early/2021/05/04/2021.05.03.21256511.abstract
AB An individual’s genetics can dramatically influence breast cancer (BC) risk. While clinical measures for prevention do exist, non-invasive personalized measures for reducing BC risk are limited. Commonly-used medications are a promising set of modifiable factors, however no previous study has explored whether a range of widely-taken approved drugs modulate BC genetics. In this study, we describe a quantitative framework for exploring the interaction between the genetic susceptibility of BC and medication usage among UK Biobank women. We computed BC polygenic scores (PGS) that summarize BC genetic risk, and find that the PGS explains nearly three-times greater variation in disease risk within corticosteroid users compared to non-users. We map 35 genes significantly interacting with corticosteroid use (FDR < 0.1), highlighting the transcription factor NRF2 as a common regulator of gene-corticosteroid interactions in BC. Finally, we discover a novel regulatory variant strongly stratifying BC risk according to corticosteroid use. Within risk allele carriers, 18.2% of women taking corticosteroids developed BC, compared to 5.1% of the non-users (with a HR = 3.41 per-allele within corticosteroid users). Overall, this work highlights the clinical relevance of gene-drug interactions in disease risk, and provides a roadmap for repurposing biobanks in drug repositioning and precision medicine.Competing Interest StatementO.E. is scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and One Three Biotech.Funding StatementSupport was provided for A.R.M. by the NIH grant R01 ES029929.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank data was accessed under application number 47137.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank data was accessed under application number 47137. Computer code to reproduce the analyses is available at https://github.com/drewmard/druggene.